108 related articles for article (PubMed ID: 17041093)
21. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Yamasaki F; Zhang D; Bartholomeusz C; Sudo T; Hortobagyi GN; Kurisu K; Ueno NT
Mol Cancer Ther; 2007 Aug; 6(8):2168-77. PubMed ID: 17671085
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
Cerniglia GJ; Pore N; Tsai JH; Schultz S; Mick R; Choe R; Xing X; Durduran T; Yodh AG; Evans SM; Koch CJ; Hahn SM; Quon H; Sehgal CM; Lee WM; Maity A
PLoS One; 2009 Aug; 4(8):e6539. PubMed ID: 19657384
[TBL] [Abstract][Full Text] [Related]
25. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun SY
Cancer Biol Ther; 2008 Dec; 7(12):1952-8. PubMed ID: 18981735
[TBL] [Abstract][Full Text] [Related]
26. Metformin and erlotinib synergize to inhibit basal breast cancer.
Lau YK; Du X; Rayannavar V; Hopkins B; Shaw J; Bessler E; Thomas T; Pires MM; Keniry M; Parsons RE; Cremers S; Szabolcs M; Maurer MA
Oncotarget; 2014 Nov; 5(21):10503-17. PubMed ID: 25361177
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Li B; Gao S; Wei F; Bellail AC; Hao C; Liu T
Oncol Rep; 2012 Jul; 28(1):15-20. PubMed ID: 22552366
[TBL] [Abstract][Full Text] [Related]
29. [Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].
Wei W; Guo RP; Li JQ; Xu L; Shi M; Zhang YQ
Ai Zheng; 2008 Apr; 27(4):386-92. PubMed ID: 18423125
[TBL] [Abstract][Full Text] [Related]
30. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
32. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
Azzariti A; Porcelli L; Gatti G; Nicolin A; Paradiso A
Biochem Pharmacol; 2008 Mar; 75(5):1035-44. PubMed ID: 18191814
[TBL] [Abstract][Full Text] [Related]
33. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
34. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
36. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
39. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]